Anuh Pharma Reports Mixed Financial Results Amidst Sales Growth and Profitability Challenges

Anuh Pharma, a microcap player in the Pharmaceuticals & Biotechnology sector, has reported its financial results for the quarter ending June 2025. The results, declared on August 8, 2025, indicate a notable shift in the company's financial evaluation. The score has experienced a revision, reflecting the challenges faced during this period.
On a positive note, Anuh Pharma's net sales for the latest six months reached Rs 384.62 crore, showcasing a year-on-year growth of 27.44%. This suggests a favorable near-term sales trend, indicating some resilience in revenue generation.

Conversely, several key metrics reveal areas of concern. The Profit After Tax (PAT) for the quarter stands at Rs 8.30 crore, which represents a significant decline compared to the average PAT of the previous four quarters. Additionally, the operating profit has reached its lowest point in the last five quarters at Rs 10.30 crore, with the operating profit margin also declining to 5.52%. Other metrics, including Profit Before Tax and Earnings per Share, have similarly shown downward trends, indicating challenges in profitability and shareholder returns.

Overall, Anuh Pharma's recent financial results highlight a complex landscape, with both positive sales growth and significant pressures on profitability metrics.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.